Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2387-2395

  Chakravarti, Arnab ^a   Delaney, Meaghan A ^a   Loeffler, Jay S ^a   Muzikansky, Alona ^b   Dyson, Nicholas J ^c   Noll, Elizabeth ^d   Black, Peter Mc L ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Biostatistics Solutions   (United States)

^c Program in Cell   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RNA DIRECTED DNA POLYMERASE; TELOMERASE;

ARTICLE; CARCINOGENESIS; CELL CYCLE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ASSAY;

BLOTTING, WESTERN; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DNA-BINDING PROTEINS; GLIOMA; HUMANS; PHOSPHORIC MONOESTER HYDROLASES; PROGNOSIS; PROTEINS; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINOBLASTOMA PROTEIN; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0034886306     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, Epidemiology, and End Results (SEER) data
2. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
3. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
4. Molecular pathogenesis of malignant gliomas
5. Comparative molecular genetic profiles of anaplastic astrocytomas/glioblastoma multiforme and their subsequent recurrences
6. Multiple sequential molecular abnormalities in the evolution of human gliomas
7. Comprehensive allelotype and genetic analysis of 466 human central nervous system tumors
8. Loss of heterozygosity on chromosome 19 in secondary glioblastomas
9. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
10. Molecular analysis of microdissected de novo glioblastomas and paired astrocytomas
11. A molecular genetic model of astrocytoma histopathology
12. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
13. Molecular genetic correlates of p16, cdk4, and pRB immunohistochemistry in glioblastomas
14. p53 mutations in malignant gliomas
15. p53 and brain tumors: From gene mutations to gene therapy
16. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas
17. Mutation of the PTEN(MMAC1) tumor suppressor in a subset of glioblastomas but not meningiomas with loss of chromosome arm 10q
18. Somatic mutations of PTEN in glioblastoma multiforme
19. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2, or bcl-2 genes
20. p16(INK4a) expression begins early in human colon neoplasia: Correlates inversely with markers of cell proliferation
21. Antibodies specific for the human retinoblastoma protein identify a family of related polypeptides
22. Positive and negative regulation of cell proliferation by E2F-1: Influence of protein level and human papillomavirus oncoproteins
23. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia
24. Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells
25. Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is dependent on the integrity of the endogenous cell cycle control pathways in human glioblastoma cell lines
26. Hypermethylation-associated inactivation of p14(ARF) is independent of p16 methylation and p53 mutational status
27. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma
28. Cdkn2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
29. Frequent alterations in the expression of tumor suppressor genes p16INK4A and pRB in esophageal squamous cell carcinoma in Indian population
30. Prognostic value of the expression of tumor suppressor genes p53, p21, p16, and pRB, and Ki-67 labelling index in high grade astrocytomas treated with radiotherapy
31. Loss of p16(INK4) protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression
32. p53-independent functions of the p19(ARF) tumor suppressor
33. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer
34. The retinoblastoma gene is involved in malignant progression of astrocytomas
35. Detection of p16 gene deletions in gliomas: A comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR
36. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas
37. Gene amplifications as a prognostic factor in primary brain tumors
38. 1-transition in clinical breast cancer tissue
39. Processing of cyclin E differs between normal and breast cells
40. Gl-S transition defects occur in most breast cancers and predicts outcome
41. Epidermal growth factor receptor and labelling index are independent prognostic factors in glial tumor outcome
42. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: An analysis of 168 cases
43. Quantitative telomerase expression in glioblastomas shows regional variation and down-regulation with therapy but no correlation with patient outcome
44. Telomeric expression in gliomas including the non-astrocytic tumors
45. Telomerase activity in microdissected human gliomas
46. Telomerase activity and alterations in telomere length in human brain tumors
47. Telomerase activity in 144 brain tumors
48. Telomerase expression shows differences across multiple regions of oligodendroglios versus high grade astrocytomas but shows correlation with Mib-1 labelling